<DOC>
	<DOCNO>NCT00507793</DOCNO>
	<brief_summary>To evaluate safety efficacy different dos cyclosporine give concomitantly fix dose sirolimus kidney transplant recipient .</brief_summary>
	<brief_title>Study Evaluating Efficacy Safety Cyclosporine Reduction Kidney Transplant Recipients Receiving Sirolimus</brief_title>
	<detailed_description>To evaluate safety efficacy different dos cyclosporine give concomitantly fix dose sirolimus kidney transplant recipient . Cyclosporine blood level , graft rejection rate renal function assess .</detailed_description>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>Inclusion criterion At least 18 year age Endstage renal disease patient receive primary secondary renal allograft cadaveric , livingunrelated , livingrelated mismatch donor Patients secondary kidney transplant must maintain primary graft least 6 month Exclusion criterion Antibody induction within one week current transplantation Multiorgan transplant Patients highrisk rejection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2007</verification_date>
</DOC>